Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget

Author:

Kapoor Ritika1,Standaert Baudouin2ORCID,Pezalla Edmund J.3,Demarteau Nadia4,Sutton Kelly5ORCID,Tichy Eszter6,Bungey George7,Arnetorp Sofie8,Bergenheim Klas8,Darroch-Thompson Duncan9,Meeraus Wilhelmine10,Okumura Lucas M.11,Tiene de Carvalho Yokota Renata1012,Gani Ray7,Nolan Terry1314

Affiliation:

1. Evidera, PPD Singapore, 08–11, 1 Fusionopolis Walk, Singapore 138628, Singapore

2. Faculty of Medicine and Life Sciences, University of Hasselt, Agoralaan, 3590 Diepenbeek, Belgium

3. Enlightenment Bioconsult, LLC, 140 S Beach Street, Suite 310, Daytona Beach, FL 32114, USA

4. Evidera, 1932 Brussels, Belgium

5. Evidera, Melbourne, VIC 3004, Australia

6. Evidera, H-1113 Budapest, Hungary

7. Evidera, PPD the Ark, 2nd Floor, 201 Talgarth Road, London W6 8BJ, UK

8. Health Economics & Payer Evidence, BioPharmaceuticals R&D, AstraZeneca, 431 83 Gothenberg, Sweden

9. International Market Access, Vaccines and Immune Therapies, AstraZeneca, Singapore 339510, Singapore

10. Medical Evidence, Vaccines and Immune Therapies, AstraZeneca, Cambridge CB2 8PA, UK

11. Health Economics & Payer Evidence, BioPharmaceuticals R&D, AstraZeneca, São Paulo 06709-000, Brazil

12. P95 Epidemiology & Pharmacovigilance, 3001 Leuven, Belgium

13. The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC 3010, Australia

14. Murdoch Children’s Research Institute, Parkville, VIC 3052, Australia

Abstract

Healthcare decision-makers face difficult decisions regarding COVID-19 booster selection given limited budgets and the need to maximize healthcare gain. A constrained optimization (CO) model was developed to identify booster allocation strategies that minimize bed-days by varying the proportion of the eligible population receiving different boosters, stratified by age, and given limited healthcare expenditure. Three booster options were included: B1, costing US $1 per dose, B2, costing US $2, and no booster (NB), costing US $0. B1 and B2 were assumed to be 55%/75% effective against mild/moderate COVID-19, respectively, and 90% effective against severe/critical COVID-19. Healthcare expenditure was limited to US$2.10 per person; the minimum expected expense using B1, B2, or NB for all. Brazil was the base-case country. The model demonstrated that B1 for those aged <70 years and B2 for those ≥70 years were optimal for minimizing bed-days. Compared with NB, bed-days were reduced by 75%, hospital admissions by 68%, and intensive care unit admissions by 90%. Total costs were reduced by 60% with medical resource use reduced by 81%. This illustrates that the CO model can be used by healthcare decision-makers to implement vaccine booster allocation strategies that provide the best healthcare outcomes in a broad range of contexts.

Funder

AstraZeneca

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3